Difference between revisions of "Crenolanib (CP-868,596)"
Jump to navigation
Jump to search
m |
m |
||
Line 9: | Line 9: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
+ | [[Category:Oral medications]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] |
Revision as of 02:24, 24 February 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation.
Preliminary Data
- Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article PubMed
Also known as
- Code name: CP-868-596